Spectrum Pharmaceuticals Inc Overview and Analysis

Spectrum Pharmaceuticals Inc is a biopharmaceutical company that has been around since 2000. It was founded by Rajesh C. Shah and was initially known as NeoPharm, Inc.

The company's name was changed to Spectrum Pharmaceuticals, Inc in 2003. This change marked a significant shift in the company's focus towards oncology and hematology.

Spectrum Pharmaceuticals has a portfolio of 10 approved products, including Fusilev, Khazara, and Marqibo. These products are used to treat various types of cancer and blood disorders.

The company's products have been approved by regulatory bodies such as the FDA in the US and the EMA in the EU.

Here's an interesting read: ACT Biotech Inc

Spectrum Pharmaceuticals had a significant annual revenue of $125.8 million in 2025.

The company's financial performance is also reflected in its analyst ratings and earnings estimates. Analysts have made predictions about the company's future earnings, with the average estimate being a loss of $0.04 per share.

Here's a breakdown of the analyst ratings and earnings estimates:

Spectrum Pharmaceuticals, Inc. had an annual revenue of $125.8 million in 2025.

Their annual revenue was significantly lower than some other companies in the industry.

The company's financials are a crucial aspect of understanding their overall performance.

Spectrum Pharmaceuticals, Inc. reported a strong revenue growth in recent years, but their annual revenue in 2025 was still relatively modest compared to other pharmaceutical companies.

Recommended read: What Does Broadcom Inc Do

When analyzing a company's financials, it's essential to consider the analyst rating and earnings estimates. The average estimate for this company's earnings is -$0.04, based on 3 analyst estimates.

The range of estimates is quite narrow, with the high estimate at -$0.01 and the low estimate at -$0.07. This suggests that analysts have a relatively clear view of the company's earnings prospects.

The company's earnings have actually improved significantly from last year, with a growth rate of 76.47% year over year. This is a notable improvement, and it's worth considering the factors that have contributed to this growth.

See what others are reading: Grab Holdings Earnings

In January 2019, Spectrum Pharmaceuticals sold its entire portfolio of hematology and oncology related products to Acrotech Biopharma USA, Inc.

The seven drugs sold had a combined sales of $76.4 million in the first three quarters of 2018.

The products sold included Fusilev, Folotyn, Zevalin, Marqibo, Beleodaq, Evomela, and Khapzory.

The divestiture of these seven marketed products infused non-dilutive capital back into the organization.

This move enabled Spectrum to further advance its two cornerstone, value driving assets.

At the helm of Spectrum Pharmaceuticals, Inc. is a team of experienced leaders who drive the company's vision forward. Joe Turgeon is the President, COO of Spectrum Pharmaceuticals, Inc.

With a strong leadership team in place, the company is well-positioned for success.

Assertio Holdings, Inc. (ASRT) is acquiring Spectrum Pharmaceuticals, Inc. (SPPI) in an all-stock and contingent value rights transaction.

The deal was announced on Tuesday, and ASRT stock immediately took a hit, trading down by 10.94 percent at $5.70 per share in the pre-market trading on Nasdaq.

Assertio expects the acquisition to add to its earnings after the conclusion of the deal, which is expected in the third quarter.

If this caught your attention, see: Johnson & Johnson - Merck Consumer Pharmaceuticals Company

Spectrum Pharmaceuticals has made significant progress in research and development, with a notable FDA-approved drug in its portfolio. ROLVEDON (eflapegrastim) was approved, formerly known as Rolontis.

The company has one drug in advanced development, Poziotinib. This is a promising development for Spectrum's pipeline.

Spectrum re-submitted an updated version of its Biologics License Application (BLA) for ROLONTIS (eflapegrastim) to the FDA in 2019. This updated version included additional information in the Chemistry, Manufacturing and Controls (CMC) section.

The company voluntarily withdrew its 2018 BLA from the FDA after receiving a request for additional CMC-related information. This decision was made to avoid delays in the review process.

Recommended read: Meyer Brothers Drug Company

Spectrum Pharmaceuticals has a diverse portfolio of oncology and hematology products, including ZEVALIN, a radioactive monoclonal antibody used to treat non-Hodgkin's lymphoma.

Their product pipeline is focused on addressing unmet medical needs in these therapeutic areas, with a goal of improving patient outcomes and quality of life.

Spectrum Pharmaceuticals has a strong commitment to research and development, with a team of experienced scientists and clinicians working to identify and develop new treatments for cancer and blood disorders.

The average person spends around 4-6 hours per day on social media, which is a significant amount of time that could be spent on more productive activities.

This excessive social media use can lead to decreased productivity, increased stress, and a higher risk of mental health issues.

According to recent studies, 70% of people check their phones within 5 minutes of waking up, setting the tone for a day of constant distraction.

The constant stream of information on social media can be overwhelming, with some people seeing up to 200-300 posts per day.

This can lead to a phenomenon known as "information fatigue", where people feel exhausted from trying to keep up with the constant flow of information.

As a result, people are turning to social media detoxes and digital decluttering as a way to regain control over their online lives.

By setting boundaries and being more mindful of our social media use, we can reduce the negative effects and make the most of this powerful tool.

You might enjoy: Can I Use My Own Modem with Spectrum?

As you dive into the world of insights and analysis, you'll likely have some questions. What is the role of data in driving business decisions? Data plays a crucial role in making informed business decisions, as seen in the article's example of a company using data to optimize supply chain operations.

One key question to consider is how to effectively communicate complex data insights to stakeholders. The article highlights the importance of using visualizations and clear language to convey data-driven messages.

What are some common pitfalls to avoid when working with data? The article notes that ignoring data quality issues can lead to inaccurate conclusions, as seen in the example of a company that incorrectly attributed sales growth to a new marketing campaign when in fact it was due to a change in market trends.

How can you ensure that your data analysis is unbiased? The article suggests using multiple data sources and considering alternative perspectives to mitigate the risk of bias.

Can data analysis be used to predict future trends? Yes, by analyzing historical data and identifying patterns, companies can make informed predictions about future market trends, as demonstrated in the article's example of a company that used data analysis to forecast sales growth.

For more insights, see: T Rowe Price Spectrum Moderate Growth Allocation Fund

Spectrum Pharmaceuticals is a biopharmaceutical company that has been around since 1987. They are a publicly traded company, listed on the NASDAQ stock exchange.

Spectrum Pharmaceuticals is headquartered in Henderson, Nevada, and has a presence in several countries worldwide. Their main focus is on developing and commercializing a range of oncology and hematology products.

Spectrum Pharmaceuticals, Inc. employs 108 people.

At least one company, Spectrum Pharmaceuticals, Inc., has a relatively small workforce.

108 is a small number of employees for a company.

Explore further: Small Business Heath Insurance

Spectrum Pharmaceuticals, Inc. is based in Lake Forest, Illinois.

Their location is in a suburb of Chicago, which is a major hub for pharmaceutical companies.

Spectrum Pharmaceuticals, Inc. is a publicly traded company, listed on the NASDAQ stock exchange.

Their company is focused on developing and commercializing a range of oncology and hematology treatments.

Spectrum Pharmaceuticals, Inc. is a relatively small company, but they have a significant presence in the pharmaceutical industry.

They have a dedicated team of professionals working on developing new treatments and improving existing ones.

The SIC code for Spectrum Pharmaceuticals, Inc. is 283, 28, 87, and 873. These codes are used to classify the company's primary business activities.

Spectrum Pharmaceuticals, Inc. has multiple SIC codes because it operates in various industries.